$8.10
0.30[3.85%]
At close: Apr 26
$8.10
0[0.00%]
After Hours: 4:20PM EDT
RAPT Therapeutics
(NASDAQ:RAPT)Latest News for RAPT Therapeutics Stock (NASDAQ:RAPT)
RAPT Therapeutics Stock (NASDAQ: RAPT)
Categories: All
Wednesday, April 10, 2024
Tuesday, April 09, 2024
Wednesday, March 27, 2024
Thursday, March 07, 2024
Tuesday, March 05, 2024
Thursday, February 22, 2024
Wednesday, February 21, 2024
- What's Going On With RAPT Therapeutics Stock On Wednesday?Vandana Singh - Feb 21, 2024, 2:04PM
- Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Feb 21, 2024, 1:50PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Feb 21, 2024, 12:31PM
- CORRECTION: RAPT Therapeutics shares are trading higher.Benzinga Newsdesk - Feb 21, 2024, 11:39AM
- RAPT Therapeutics shares are trading higher on a rebound amid increased volatility in the stock, which sold off yesterday after the company announced the FDA placed a clinical hold on its Phase 2b trial of zelnecirnon.Benzinga Newsdesk - Feb 21, 2024, 11:11AM
- Leerink Partners Downgrades RAPT Therapeutics to Market Perform, Announces $10 Price TargetBenzinga Newsdesk - Feb 21, 2024, 7:21AM
- HC Wainwright & Co. Downgrades RAPT Therapeutics to NeutralBenzinga Newsdesk - Feb 21, 2024, 6:42AM
Tuesday, February 20, 2024
- Crude Oil Moves Lower; Summit Therapeutics Shares PlummetAvi Kapoor - Feb 20, 2024, 2:33PM
- Cantor Fitzgerald Downgrades RAPT Therapeutics to NeutralBenzinga Newsdesk - Feb 20, 2024, 2:14PM
- Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Feb 20, 2024, 1:21PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Feb 20, 2024, 12:31PM
- Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeutics Shares Tumbling Today?Vandana Singh - Feb 20, 2024, 12:24PM
- Rapt Therapeutics shares are trading lower after the FDA verbally notified clinical hold on the company's Phase 2B trial of zelnecirnon in atopic dermatitis and Phase 2A trial in asthma.Benzinga Newsdesk - Feb 20, 2024, 12:15PM
- Dow Dips Over 100 Points; US Leading Economic Index Falls In JanuaryAvi Kapoor - Feb 20, 2024, 12:09PM
- Nasdaq Down 1%; Capital One Set To Buy DiscoverAvi Kapoor - Feb 20, 2024, 9:54AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Feb 20, 2024, 8:05AM
- Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga Newsdesk - Feb 20, 2024, 7:55AM
- Rapt Therapeutics Announced That The FDA Has Verbally Notified Of A Clinical Hold Placed On The Company's Phase 2B Trial Of Zelnecirnon (RPT193) In Atopic Dermatitis And Its Phase 2A Trial In AsthmaBenzinga Newsdesk - Feb 20, 2024, 7:35AM
- Trading Halt: Halted at 7:25:12 a.m. ET - Trading Halt: Halt News PendingBenzinga Newsdesk - Feb 20, 2024, 7:25AM
Friday, February 16, 2024
Thursday, February 15, 2024
Thursday, November 30, 2023
Monday, November 27, 2023
Wednesday, November 15, 2023
Monday, November 13, 2023
Wednesday, October 18, 2023
Wednesday, October 04, 2023
Tuesday, October 03, 2023
Thursday, September 14, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023Benzinga Insights - Sep 14, 2023, 11:00AM
- Analyst Ratings for RAPT TherapeuticsBenzinga Insights - Sep 14, 2023, 8:00AM
- Berenberg Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $34Benzinga Newsdesk - Sep 14, 2023, 5:13AM
Wednesday, August 16, 2023
- RAPT Therapeutics shares are trading lower after JP Morgan maintained an Overweight rating on the stock but lowered its price target from $39 to $32.Benzinga Newsdesk - Aug 16, 2023, 12:26PM
- JP Morgan Maintains Overweight on RAPT Therapeutics, Lowers Price Target to $32Benzinga Newsdesk - Aug 16, 2023, 9:17AM
Monday, August 14, 2023
Friday, August 11, 2023
Wednesday, August 09, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023Benzinga Insights - Aug 9, 2023, 11:00AM
- The Latest Analyst Ratings for RAPT TherapeuticsBenzinga Insights - Aug 9, 2023, 10:00AM
- Stifel Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $40Benzinga Newsdesk - Aug 9, 2023, 5:12AM